Recursion Pharmaceuticals

Recursion runs millions of cellular experiments a week, imaging how cells respond to genetic and chemical perturbations and using machine learning to spot patterns at a volume no human analysis could match. It merged with Exscientia in 2024 to form a larger combined AI drug discovery company, pooling Recursion's high-throughput biology with Exscientia's own AI-designed drug candidates across a broader therapeutic pipeline.